Trial reportParasite (Paris, France)2016
Efficacy of afoxolaner in a clinical field study in dogs naturally infested with Sarcoptes scabiei.
Trial report in Parasite (Paris, France), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- Assessment of the insecticidal activity of afoxolaner against Aedes aegypti in dogs treated with NexGardParasite (Paris, France) · 2017Trial
- Efficacy of afoxolaner or a combination of afoxolaner and milbemycin oxime against fleas, ticks, lice and/or intestinal nematodes in dogs naturally infested in two urban areas in Brazil.Parasites & vectors · 2026Article
- Inhibitory effects of terpenes on Sarcoptes scabiei in the molting stage.BMC veterinary research · 2026Article
- Field efficacy assessment of a combination of afoxolaner, moxidectin and pyrantel pamoate to treat dogs naturally infested with Sarcoptes scabiei.Parasite (Paris, France) · 2026Article
- The safety and efficacy of topical clove oil for the treatment of naturally occurringFrontiers in veterinary science · 2026Article
- Efficacy of an oral formulation of afoxolaner and milbemycin oxime against Tunga penetrans in naturally infected dogs.Parasites & vectors · 2023Article
- Isoxazolines for treating canine demodicosis, sarcoptic mange (scabies), and lice infestation.The Canadian veterinary journal = La revue veterinaire canadienne · 2022Article
- Efficacy of afoxolaner (NexGard®) against natural infestations with Trichodectes canis in dogs under field conditions.Parasites & vectors · 2022Article
- A double-blinded placebo-controlled evaluation of adipose-derived mesenchymal stem cells in treatment of canine atopic dermatitis.Veterinary research communications · 2022Article
- Fluralaner as a novel treatment for sarcoptic mange in the bare-nosed wombat (Vombatus ursinus): safety, pharmacokinetics, efficacy and practicable use.Parasites & vectors · 2021Article
- Insecticidal efficacy of afoxolaner against bedbugs, Cimex lectularius, when administered orally to dogs.Parasite (Paris, France) · 2021Article
- Clinical, Parasitological, and Serological Follow-Up of Dogs with Sarcoptic Mange Treated Orally with Lotilaner.Case reports in veterinary medicine · 2021Article
- Efficacy of a novel topical combination of esafoxolaner, eprinomectin and praziquantel against ear mite (Otodectes cynotis) infestations in cats.Parasite (Paris, France) · 2021Article
- Efficacy of orally and topically administered fluralaner (BravectoParasites & vectors · 2020Article
- Efficacy of combination products containing sarolaner, moxidectin and pyrantel (Simparica Trio™) or afoxolaner and milbemycin (NexGard SpectraParasites & vectors · 2020Article
- Efficacy of afoxolaner plus milbemycin oxime and afoxolaner alone as treatment for sarcoptic mange in naturally infested dogs.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2020Article
- Afoxolaner as a Treatment for a NovelFrontiers in veterinary science · 2020Article
- A review of sarcoptic mange in North American wildlife.International journal for parasitology. Parasites and wildlife · 2019Review
- Assessment of the insecticidal activity of oral afoxolaner against Phlebotomus perniciosus in dogs.Parasite (Paris, France) · 2019Article
- Efficacy of two formulations of afoxolaner (NexGard® and NexGard Spectra®) for the treatment of generalised demodicosis in dogs, in veterinary dermatology referral centers in Europe.Parasites & vectors · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acaricidal efficacy of afoxolaner (NexGard(®), Merial) was evaluated against Sarcoptes scabiei var. canis in a field efficacy study, when administered orally at a minimum dose of 2.5 mg/kg to dogs naturally infested with the mites. Twenty mixed-breed dogs of either sex (6 males and 14 females), aged over 6 months and weighing 4-18 kg, were studied in this randomised controlled field efficacy trial. Dogs, naturally infested with Sarcoptes scabiei var. canis confirmed by skin scrapings collected prior to allocation, were randomly divided into two equal groups. Dogs in Group 1 were not treated. Dogs in Group 2 were treated on Days 0 and 28. On Days 0 (pre-treatment), 28 (pre-treatment) and 56, five skin scrapings of similar size were taken from different sites with lesions suggestive of sarcoptic mange. The extent of lesions was also recorded on Days 0, 28 and 56, and photographs were taken. Dogs treated orally with afoxolaner had significantly (p < 0.001) lower mite counts than untreated control animals at Days 28 and 56 with no mites recovered from treated dogs at these times (100% efficacy based on mite counts). In addition, dogs treated with NexGard had significantly (p < 0.05) better lesion resolution at Day 56 than Day 0; no treated dog showed pruritus compared to 7/10 dogs in the control group, 1/9 treated dogs had crusts compared to 5/10 controls and 8/9 dogs recovered 90% of hairs on lesions compared to 0/10 control dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.